A phase 1 clinical study of a selective HDAC6 inhibitor (SP-2-225)
Latest Information Update: 05 Apr 2023
At a glance
- Drugs SP 2 225 (Primary)
- Indications Breast cancer; Lung cancer; Malignant melanoma; Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 05 Apr 2023 New trial record
- 22 Mar 2023 According to a Shuttle Pharmaceuticals media release, goal of company is to submit an investigational new drug application (IND) for their IND-enabling studies for selective HDAC6 inhibitor and initiation of a Phase I clinical trial in 2024.